All patients | High Responder | Low Responder | p | |
---|---|---|---|---|
Age (yrs ± SD) | 70 ± 11 | 67 ± 25 | 72 ± 11 | 0.15 |
Male n (%) | 29 (64) | 15 (75) | 14 (56) | 0.19 |
BMI (kg/m2 ± SD) | 27 ± 5 | 27 ± 5 | 27 ± 5 | 0.69 |
Grade of MR n (%) | 0.86 | |||
4+ | 33 (73) | 14 (70) | 19 (76) | |
3+ | 5 (11) | 4 (20) | 1 (4) | |
2+ | 7 (16) | 2 (10) | 5 (20) | |
NYHA n (%) | 0.06 | |||
IV | 8 (18) | 4 (20) | 4 (16) | |
III–IV | 11 (24) | 8 (40) | 3 (12) | |
III | 15 (33) | 5 (25) | 10 (40) | |
II–III | 8 (18) | 3 (15) | 5 (20) | |
II | 3 (7) | 0 | 3 (12) | |
Previous interventions n (%) | ||||
CABG or PCI | 12 (27) | 5 (25) | 7 (28) | 0.82 |
Valve surgery | 4 (9) | 1 (5) | 3 (12) | 0.42 |
ICD | 13 (29) | 8 (40) | 5 (20) | 0.15 |
CRT | 9 (20) | 3 (15) | 6 (24) | 0.46 |
Comorbidities n (%) | ||||
AF | 30 (67) | 9 (45) | 21 (84) | 0.005 |
SR | 21 (47) | 12 (6) | 9 (36) | 0.11 |
CAD | 29 (64) | 11 (55) | 18 (72) | 0.25 |
Previous MI | 15 (33) | 5 25) | 10 (40) | 0.30 |
COPD | 8 (18) | 5 (25) | 3 (12) | 0.27 |
pHTN | 29 (64) | 14 (70) | 15 (60) | 0.51 |
Logistic EuroSCORE (% ± SD) | 17 ± 17 (6–21) | 16 ± 17 | 133 ± 17 (6–19) | 0.84 |
Medication n (%) | ||||
ACE inhibitors/ARB | 29 (64) | 13 (65) | 16 (64) | 0.95 |
AT1-antagonists | 6 (13) | 4 (20) | 2 (8) | 0.25 |
Beta-blockers | 41 (91) | 18 (90) | 23 (92) | 0.82 |
Loop diuretics | 36 (80) | 16 (80) | 20 (80) | 1 |
Aldosterone antagonists | 22 (49) | 12 (60) | 10 (40) | 0.19 |